Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 5 - Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof
Patents for C07K 5 - Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof (30,692)
06/2005
06/08/2005EP1538160A1 Substituted Isoquinolin-3-carboxyamides, their preparation and medical use
06/08/2005EP1538159A1 Substituted N-benzyl-lactam derivatives as melanocortin-4 receptor agonists
06/08/2005EP1538158A1 Proline ester and preparation containing the same for percutaneous administration
06/08/2005EP1538157A2 Isolation and use of SH3 binding peptides
06/08/2005EP1538156A1 Versatile linker compound and ligand, and method for preparation thereof
06/08/2005EP1537230A1 Fluorescent enzyme assay methods and compositions
06/08/2005EP1536813A2 Compositions and methods comprising protein activated receptor antagonists
06/08/2005EP0849256B1 Amide compounds and use of the same
06/08/2005CN1623993A Cantharides amine and demethyl cantharides amine derivative and application in medicine thereof
06/08/2005CN1205186C ACE inhibitor nitric salts
06/07/2005US6903075 Fibronectin antagonists such as N-(3,4-dimethoxybenzene-sulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S) -carbonyl-(L)-leucine, used for prophylaxis asthma, allergies, inflammation, multiple sclerosis and autoimmune disorders
06/02/2005WO2005050291A1 Translating bifocal wear modality
06/02/2005WO2005049819A1 Antibacterial peptide and utilization of the same
06/02/2005WO2005018575A3 Estrogen receptor modulators and uses thereof
06/02/2005WO2005016958A3 Compounds for treating tumors
06/02/2005WO2005010027A3 Novel peptidic conjugates for alopecia preventive and curative treatment
06/02/2005WO2004112572A3 Monitoring immunologic, hematologic and inflammatory diseases
06/02/2005WO2004094457A3 Stable rgd peptidomimetic composition
06/02/2005WO2004065547A3 Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods
06/02/2005US20050119486 Diamine derivatives
06/02/2005US20050119453 Method of removing transition metals
06/02/2005US20050119247 Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
06/02/2005US20050119245 Alpha -, beta -, and gamma -amino acid derivatives, e.g., S)-2-{N'-[4-(4-Fluoro-phenoxy)-phenyl]-N''-cyano-guanidino}-3-phenyl-N-(3-pyrrolidin-1-yl-propyl)-propionamide for the treatment of central nervous system conditions such as muscle spasticity, tinnitus, epilepsy and neuropathic pain.
06/02/2005US20050119190 Anticoagulants; cardiovascular disorders; thrombosis
06/02/2005US20050119189 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
06/02/2005US20050119187 Anti-fibril peptides
06/02/2005US20050119184 Immunoregulator
06/02/2005US20050119176 Core structure polypeptide; libraries; inhibition of apoptosis; anticancer agents; autoimmune disease; skin disorders; restenosis
06/02/2005US20050119169 Spatially-defined macrocycles incorporating peptide bond surrogates
06/02/2005US20050119168 Macrocyclic inhibitors of hepatitis C virus NS3-serine protease
06/02/2005US20050119163 Prevent binding to phosphoprotein; cancer therapy; angiogenesis inhibitor
06/02/2005US20050118646 Using affinity matrix to isolating cluster of macromolecules comprising protein stabilized by non-covalent bonds; drug screening; high throughput assay
06/02/2005US20050118101 Delivery across skin or blood brain barrier; such as N-(fluorescein-5-yl)-thioureido-N'-Adoa-(polylysine)7-NH2 TFA salt
06/02/2005CA2545266A1 Translating bifocal wear modality
06/01/2005EP1534736A2 Nogo receptor antagonists
06/01/2005EP1534718A1 Chemical synthesis of reagents for peptide coupling
06/01/2005EP1534310A2 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
06/01/2005EP1534308A2 Peptides with growth inhibitory action
06/01/2005EP1254179A4 An in vivo screen using chemical inducers of dimerization
06/01/2005EP1009758B1 Meta-benzamidine derivatives as serine protease inhibitors
06/01/2005CN1622954A Intermediates for LHRH antagonist synthesis, process for their production, and process for LHRH antagonist production
06/01/2005CN1622953A Peptide derivative, and pharmaceutically acceptable salt thereof, process for producing the same, and use thereof
06/01/2005CN1622942A HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
06/01/2005CN1622941A Glutaminyl based DPIV inhibitors
06/01/2005CN1204144C Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
06/01/2005CN1204143C Crystalline forms of EtO2C-CH2-(R)Cgl-Aze-Pab-OH
05/2005
05/31/2005US6900319 Carbo- and heterocyclic amidines
05/31/2005US6900317 Calcitonin gene related peptide antagonist; spray dried powder
05/31/2005US6900218 Reducing oxidation stresses; central nervous system disorders; antiinflammatory agents
05/31/2005US6900213 Controlling fertility; contraceptives; anticancer agents
05/31/2005US6900192 Bile-acid conjugates for providing sustained systemic concentrations of drugs
05/31/2005US6900179 Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
05/31/2005US6899912 Reacting aspartame with 3-(3-methoxy-4-hydroxyphenyl)propional
05/26/2005WO2005047312A1 Beauveriolide derivative
05/26/2005WO2005047311A1 Beauveriolide derivatives
05/26/2005WO2005046712A1 Hepatitis c virus inhibitors
05/26/2005WO2005046575A2 Amino acid prodrugs
05/26/2005WO2005009363A3 Treatment of pre-cancerous conditions and prevention of cancer using pcdgf-based therapies
05/26/2005WO2005009217A3 Diagnosis of pre-cancerous conditions using pcdgf agents
05/26/2005WO2004099784A3 Method for determining a tissue degradation process by detection of fibromodulin neoepitopes
05/26/2005US20050113309 Useful as thrombin inhibitors
05/26/2005US20050113308 Pentapetide containing a proline amino acid; cytotoxic agent
05/26/2005US20050113295 Carboxamide and amino derivatives and methods of their use
05/26/2005US20050113294 Carboxamide and amino derivatives and methods of their use
05/26/2005US20050113292 Protein mimetic for preventing HIV-1 entry to host cells of living subject through membrane fusion, wherein HIV-1 contains envelope glycoprotein gp41 that has plurality of peptides in pre-hairpin state, comprising at least two monomeric peptide strands and interstrand linker coupling peptide strands
05/26/2005US20050112185 Positively charged lipid and liposome with the lipid
05/26/2005CA2534342A1 Amino acid prodrugs
05/25/2005EP1533318A1 Prodrugs of thrombin inhibitors
05/25/2005EP1533300A1 Organic amine salts of glutamic acid derivatives and their application
05/25/2005EP1533025A2 Microwave-assisted peptide synthesis
05/25/2005EP1532262A2 Petide amidation process
05/25/2005EP1532164A1 Template-fixed peptidomimetics with antibacterial activity
05/25/2005EP1531852A1 Caspase 9 activation and uses therefor
05/25/2005EP1531846A2 Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
05/25/2005EP1417219A4 Libraries of conformationally constrained peptides, chiral azacrowns, and peptidomimetics and methods of making the same
05/25/2005EP1286673B1 Ligands of integrin receptors
05/25/2005EP1097164A4 Processes for coupling amino acids using bis-(trichloromethyl) carbonate
05/25/2005EP0967221B1 Process for preparing pharmacologically acceptable salts of n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanyl amino acids
05/25/2005EP0733060B1 Metal chelators
05/25/2005DE10392821T5 Synteseverfahrens für Alanylglutamin Synteseverfahrens for alanylglutamine
05/25/2005CN1618789A Macrocyclic peptides active against the hepatitis C virus
05/25/2005CN1203087C Factor VIIa inhibitors
05/24/2005US6897306 3-heterocyclylpropanohydroxamic acids
05/24/2005US6897034 Antitumor agents; drug immobilized to oligopeptide; complexing; testing, calibration of complex to see if capable of being split enzyme; drug design
05/24/2005CA2157792C N-(3-piperidinyl-carbonyl)-beta-alanine derivatives as paf antagonists
05/21/2005CA2486838A1 Organic amine salts of glutamic acid derivatives and their application
05/19/2005WO2005045006A1 Microbe capable of producing dipeptide and process for producing dipeptide with the microbe
05/19/2005WO2005044839A2 Stabilized alpha helical peptides and uses thereof
05/19/2005WO2005044810A1 Glyt2 modulators
05/19/2005WO2005007079A3 Inactivators and bivalent inhibitors of glyoxalase i and methods of inhibiting tumor growth
05/19/2005WO2004097406A3 Nϵ AND/OR Nα DERIVATIZED, METAL AND ORGANIC PROTECTED L-HISTIDINE FOR COUPLING TO BIOMOLECULES FOR HIGHLY EFFICIENT LABELING WITH [M(OH2)3(CO)3]+ BY FAC COORDINATION
05/19/2005WO2004094452A3 Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
05/19/2005WO2004087743A3 Anti-hypertensive peptide derivatives and process for preparation thereof
05/19/2005US20050107543 Fluoro linkers and their use as linkers for enzyme-activated drug conjugates
05/19/2005US20050107305 Novel chromogenic substances and use thereof for the determination of carboxypeptidase activities
05/19/2005US20050107289 Anti-microbial peptides and compositions
05/19/2005US20050106727 Peptides for enhanced cell attachment and growth
05/19/2005US20050106703 Oligomerization of an amino acid or amino acid amide in presence of a microorganism of genus Escherichia, Bacillus, Corynebacterium or Saccharomyces in which the activities peptidases and proteins having peptide-transporting activity is reduced or lost
05/19/2005CA2830063A1 Stabilized alpha helical peptides and uses thereof
05/19/2005CA2544223A1 Stabilized alpha helical peptides and uses thereof
1 ... 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 ... 307